[go: up one dir, main page]

MXPA02009590A - Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos. - Google Patents

Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.

Info

Publication number
MXPA02009590A
MXPA02009590A MXPA02009590A MXPA02009590A MXPA02009590A MX PA02009590 A MXPA02009590 A MX PA02009590A MX PA02009590 A MXPA02009590 A MX PA02009590A MX PA02009590 A MXPA02009590 A MX PA02009590A MX PA02009590 A MXPA02009590 A MX PA02009590A
Authority
MX
Mexico
Prior art keywords
compounds
vitamin
group
diseases
hydrogen
Prior art date
Application number
MXPA02009590A
Other languages
English (en)
Inventor
Hector F Deluca
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of MXPA02009590A publication Critical patent/MXPA02009590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invencion proporciona una clase novedosa de compuestos relacionados con vitamina D, es decir derivados de 2-alquiliden-19-norvitamina D, asi como a un metodo general para su sintesis quimica. Los compuestos tienen la formula (I), en donde Y1 e Y2, que pueden ser iguales o diferentes, cada uno se elige del grupo que consiste de hidrogeno y un grupo protector hidroxi, R6 y R8, que pueden ser iguales o diferentes, cada uno se elige de hidrogeno, alquilo, hidroxialquilo y fluoroalquilo, o cuando se toman juntos representan el grupo -(CH2)x- en donde x es un entero de 2 a 5, y en donde el grupo R representa cualquiera de las cadenas secundarias tipicas conocidas para compuestos de tipo vitamina D. Estos compuestos 2-substituidos se caracterizan por actividad de transporte de calcio intestinal relativamente elevada y actividad de mobilizacion de calcio en huesos relativamente alta, resultando en agentes terapeuticos novedosos para el tratamiento de enfermedades en donde se desea formacion de huesos, particularmente osteoporosis de bajo recambio oseo. Estos compuestos tambien exhiben pronunciada actividad para frenar la proliferacion de celulas no diferenciadas e inducir su diferenciacion al monocito de esta manera evidenciando uso como agentes anti-cancer y para el tratamiento de enfermedades tales como psoriasis.
MXPA02009590A 2000-03-31 2001-03-29 Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos. MXPA02009590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/540,686 US6392071B1 (en) 1997-03-17 2000-03-31 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
PCT/US2001/010317 WO2001074766A1 (en) 2000-03-31 2001-03-29 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses

Publications (1)

Publication Number Publication Date
MXPA02009590A true MXPA02009590A (es) 2004-03-26

Family

ID=24156520

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009590A MXPA02009590A (es) 2000-03-31 2001-03-29 Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.

Country Status (14)

Country Link
US (5) US6392071B1 (es)
EP (1) EP1268416B1 (es)
JP (1) JP4022071B2 (es)
KR (1) KR20020091167A (es)
AT (1) ATE374178T1 (es)
AU (2) AU2001247905B2 (es)
CA (1) CA2404548C (es)
DE (1) DE60130640T2 (es)
DK (1) DK1268416T3 (es)
ES (1) ES2291305T3 (es)
IL (1) IL152020A (es)
MX (1) MXPA02009590A (es)
NZ (1) NZ522160A (es)
WO (1) WO2001074766A1 (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6627622B2 (en) 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
DE60229430D1 (de) * 2001-12-13 2008-11-27 Wisconsin Alumni Res Found (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
EP1559708A4 (en) * 2002-10-10 2006-07-19 Wisconsin Alumni Res Found 2,2-DISUBSTITUTED 1A, 25-DIHYDROXY-19-NORVITAMINE D DERIVATIVE
WO2004076468A1 (ja) 2003-02-25 2004-09-10 Kobe Tennenbutsu Kagaku Kabushiki Kaisha ビタミンｄ誘導体を合成するための新規な中間体
NZ542674A (en) * 2003-04-10 2009-03-31 Wisconsin Alumni Res Found 2-Propylidene-19-nor-vitamin D compounds
WO2004098507A2 (en) * 2003-04-30 2004-11-18 Bioxell S.P.A. 1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
MXPA06000060A (es) * 2003-07-03 2006-04-07 Wisconsin Alumni Res Found 2-metilen-19-nor-20(s)-25-metil-1alfa-hidroxicalciferol y sus usos.
US20050009792A1 (en) * 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
AU2004266706B2 (en) * 2003-08-20 2009-07-30 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin D2 compounds
WO2005027922A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of hypogonadism or andropause
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
WO2005027918A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a cyclooxgenase-2 inhibitor
WO2005027928A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
EP1689412A4 (en) * 2003-11-25 2009-03-11 Wisconsin Alumni Res Found VITAMIN D ANALOGUE FOR THE PREVENTION AND TREATMENT OF ADIPOSITAS
US7053075B2 (en) * 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
WO2005079464A2 (en) * 2004-02-17 2005-09-01 Wisconsin Alumni Research Foundation Vitamin d receptor antagonists and their use in treating asthma
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
EP1812011A1 (en) 2004-11-12 2007-08-01 Bioxell S.p.a. Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
NZ555561A (en) * 2004-11-22 2009-02-28 Wisconsin Alumni Res Found 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol (a Vitamin D derivative)
CA2588060A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s)-1alpha-hydroxy-trishomopregnacalciferol
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
US8222235B2 (en) * 2004-11-22 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol
CA2588396C (en) * 2004-11-22 2013-04-23 Wisconsin Alumni Research Foundation 17,20(e)-dehydro vitamin d analogs and their uses
CA2597568A1 (en) * 2005-02-11 2006-08-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24epi)-1.alpha.,25-dihydroxyvitamin-d2
MX2007009726A (es) * 2005-02-11 2007-09-26 Wisconsin Alumni Res Found 2-metilen-19-nor-(20s-24s)-1a, 25-dihidroxivitamina-d2.
MX2007011919A (es) * 2005-03-29 2007-11-22 Wisconsin Alumni Res Found 2-metilen-19-nor-(23s)-25-deshidro-1a-hidroxivitamina d3-26,23-lactona y 2-metilen19-nor-(23r)-25-deshidro-1a- hidroxivitamina d3-26,23-lactona.
EP1877063A4 (en) * 2005-05-03 2009-11-04 Wisconsin Alumni Res Found 19,26,27-TRINOR-1ALPHA, 25-DIHYDROXYVITAMINE-D3 COMPOUNDS
WO2007028000A2 (en) 2005-08-30 2007-03-08 Wisconsin Alumni Research Foundation Des-c,d analogs of 1alpha,25-dihydroxy-19-norvitamin d3
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
US8058265B2 (en) * 2006-04-05 2011-11-15 Wisconsin Alumni Research Foundation 1a-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin D compounds and methods of making and treatment thereof
US20090281340A1 (en) * 2006-04-05 2009-11-12 Deluca Hector F 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
MX2008012672A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-18,19,21-trinor vitamina d3 y sus usos.
EP2046737B1 (en) * 2006-04-06 2011-09-07 Wisconsin Alumni Research Foundation 2-methylene-1 alpha,25-dihydroxy-19,21-dinorvitamin d3 analogs and uses thereof
JP2009533483A (ja) * 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
US7648972B2 (en) * 2006-04-06 2010-01-19 Wisconsin Alumni Research Foundation 2-methylene-1α-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
CA2647981A1 (en) * 2006-04-06 2008-03-06 Wisconsin Alumni Research Foundation 19-nor-vitamin d analogs with 1,2,or 3,2 heterocyclic ring
DE602007012216D1 (de) * 2006-04-10 2011-03-10 Wisconsin Alumni Res Found 1-alpha-hydroxy-2-(3'-hydroxypropyliden)-19-nor-vitamin-d-verbindungen mit einer 1,1-dimethylpropyl-seitenkette
US20080171728A1 (en) * 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
US8377913B2 (en) * 2007-11-20 2013-02-19 Abbvie Inc. Vitamin D receptor activators and methods of making
CA2712748A1 (en) * 2008-01-22 2009-07-30 Wisconsin Alumni Reasearch Foundation 13,13-dimethyl-des-c,d analogs of 1.alpha.,25-dihydroxy-19-nor-vitamin d3 compounds and topical composition dosage forms and methods of treating skin conditions thereof
JP2011513428A (ja) * 2008-03-06 2011-04-28 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン １９−ノル含有ビタミンｄ化合物の局所投与によって表皮の厚さを増す方法
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
CN107019795A (zh) * 2009-01-27 2017-08-08 博格有限责任公司 用于减轻与化疗有关的副作用的维生素d3化合物
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
AU2010300539B9 (en) * 2009-10-02 2018-07-19 Wisconsin Alumni Research Foundation 1-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
US8217023B2 (en) 2009-10-02 2012-07-10 Wisconsin Alumni Research Foundation 19-nor-vitamin D analogs with 1,2- or 3,2-cyclopentene ring
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
AU2011232633B2 (en) * 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
AU2011232562B2 (en) * 2010-03-23 2014-10-02 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25- dihydroxyvitamin D3
AU2012262174B2 (en) 2011-06-03 2016-12-01 Wisconsin Alumni Research Foundation (22E)-2-methylene-26,27-cyclo-22-dehydro-1alpha-hydroxy-19-norvitamin D3 derivatives
US8993547B2 (en) 2011-06-14 2015-03-31 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
AU2012326538B2 (en) 2011-10-21 2016-12-08 Wisconsin Alumni Research Foundation 2-methylene-vitamin D analogs and their uses
JP6114292B2 (ja) 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
US8785422B2 (en) 2012-06-06 2014-07-22 Wisconsin Alumni Research Foundation A-ring modified 19-nor-vitamin D analogs and their uses
KR20160013201A (ko) 2013-05-29 2016-02-03 버그 엘엘씨 비타민 d를 이용한 화학요법 유발 탈모증의 예방 또는 완화

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2114570B (en) 1981-11-02 1985-08-07 Res Inst Medicine Chem Chemical compounds
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US4800198A (en) * 1985-04-23 1989-01-24 Wisconsin Alumni Research Foundation Method of inducing the differentiation of malignant cells with secosterol
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
DK0474517T3 (da) 1990-09-07 1999-08-02 Wisconsin Alumni Res Found Hidtil ukendt anvendelse af 1alfa-hydroxyleret-19-nor-vitamin D-
US5089641A (en) * 1991-03-11 1992-02-18 Wisconsin Alumni Research Foundation Synthesis of 1α-hydroxy-secosterol compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
ZA924811B (en) 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
AU4235696A (en) 1994-11-21 1996-06-17 Wisconsin Alumni Research Foundation 18,19-dinor-vitamin d compounds
US5877168A (en) 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
IL118156A (en) 1995-05-09 2001-08-26 Duphar Int Res Vitamin d compounds, their preparation and pharmaceutical compositions containing them
AU5886096A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
HUP9801059A3 (en) * 1995-06-14 1999-05-28 Schering Ag Vitamin d derivatives with c-25 substituents, process for their preparation, intermediate products and their use in preparing medicaments
US6566351B1 (en) * 1995-12-28 2003-05-20 Chugai Seiyaku Kabushiki Kaisha Malignant tumor metastasis inhibitors
US5849960A (en) * 1996-11-26 1998-12-15 Shell Oil Company Highly branched primary alcohol compositions, and biodegradable detergents made therefrom
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6573256B2 (en) * 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5936105A (en) 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
US5962707A (en) 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
US6806262B2 (en) * 2000-05-31 2004-10-19 Wisconsin Alumni Research Foundation 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
DE60105035T2 (de) * 2000-09-08 2005-08-18 Wisconsin Alumni Research Foundation, Madison 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol und seine therapeutische verwendungen
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses

Also Published As

Publication number Publication date
ES2291305T3 (es) 2008-03-01
AU4790501A (en) 2001-10-15
JP2003529581A (ja) 2003-10-07
ATE374178T1 (de) 2007-10-15
DK1268416T3 (da) 2008-02-04
AU2001247905B2 (en) 2005-05-19
US20030181427A1 (en) 2003-09-25
DE60130640T2 (de) 2008-07-17
DE60130640D1 (de) 2007-11-08
US20040167104A1 (en) 2004-08-26
EP1268416A1 (en) 2003-01-02
NZ522160A (en) 2004-11-26
EP1268416B1 (en) 2007-09-26
US20020087015A1 (en) 2002-07-04
WO2001074766A1 (en) 2001-10-11
KR20020091167A (ko) 2002-12-05
JP4022071B2 (ja) 2007-12-12
US6392071B1 (en) 2002-05-21
CA2404548C (en) 2009-07-21
IL152020A (en) 2008-03-20
US20090143342A1 (en) 2009-06-04
US6537981B2 (en) 2003-03-25
US6696431B2 (en) 2004-02-24
CA2404548A1 (en) 2001-10-11
IL152020A0 (en) 2003-04-10
US7094774B2 (en) 2006-08-22

Similar Documents

Publication Publication Date Title
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
BR9808010A (pt) Compostos de 2-alquil-19-nor-vitamina d
PT970047E (pt) Compostos de 2-alquilideno-19-nor-vitamina d
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
DK0726892T3 (da) (E)-20(22)-dehydrovitamin D-forbindelser
BR0112857A (pt) Compostos 2-(4-piridil)amino-6-dialcoxifenil-pirido-[2,3-d]pirimidin- 7-onas
GB0121337D0 (en) Chemical compounds
GB0121622D0 (en) Chemical compounds
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
GB0121621D0 (en) Chemical compounds
ZA200406813B (en) Glytaminyl based DPIV inhibitors
MY137508A (en) Chemical compounds
HUT72436A (en) Process for the production of imidazopyridines and pharmaceutical compositions containing them and which are suitable for treating gastro-intestinal diseases
ZA9810735B (en) Novel benzenesulfonamide inhibitors of pde-iv and their therapeutic use
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
DK1056704T3 (da) Antitumormidler
AU1022999A (en) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analogs
ID28365A (id) Turunan produk alami yang baru
BR0010560A (pt) 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados
AU2003246402A1 (en) Treatment of congenital disorders of glycosylation (cdg) using mannose
DK1641466T3 (da) 2-methylen-19-nor-20(S)-25-methyl-1alfa-hydroxycalciferol og dens anvendelser
WO2000019989A3 (de) Verwendung von katecholderivaten als proteinaseinhibitoren

Legal Events

Date Code Title Description
FG Grant or registration